An Observational Study For Ambrisentan

A Post-Marketing Observational Surveillance Programme for Ambrisentan (VOLT)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00679224

Acronym

VOLT

Enrollment

800

Registered

2008-05-16

Start date

2008-06-30

Completion date

2013-07-31

Last updated

2017-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Pulmonary

Keywords

Pulmonary Arterial Hypertesion, observational safety

Brief summary

The purpose of the programme is to collect safety data on ambrisentan when used in clinical practice

Detailed description

The purpose of the programme is to collect safety data on ambrisentan when used in clinical practice

Interventions

DRUGambrisentan

ambrisentan

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

subjects who have been prescribed ambrisentan for a medically appropriate use (see approved product label)

Design outcomes

Primary

Measure	Time frame
safety monitoring	—

Secondary

Measure	Time frame
safety monitoring	—

Countries

Australia, Belgium, Canada, Czechia, Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Slovakia, Spain, Sweden, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026